Drugs / 177Lu-DOTA-rosopatamab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04876651 | Aug 2023 → Jul 2025 | metastatic prostate carcinoma | Telix Pharmaceuticals (Innovations) Pty Limited | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-DOTA-rosopatamab | “The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only” NCT04876651 ↗ |
| Modality | Monoclonal antibody | “the PSMA-targeted antibody, 177Lu DOTA rosopatamab” NCT04876651 ↗ |
| Route | Intravenous | “Two single intravenous (IV) injections of 76 mCi each” NCT04876651 ↗ |